CARLSBAD, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2020, and recent corporate highlights.
Second Quarter 2020 Financial Results
- Total revenue of $29.6 million; U.S. revenue of $28.8 million, up 11% year-over-year;
- U.S. gross margin of 72.3%; and
- Cash and cash equivalents of $31.2 million as of June 30, 2020.
Recent Corporate Highlights
- Increased contribution from new products to 61% of Q2 U.S. revenue, up from 32% in Q2 2019;
- Increased U.S. revenue and average product categories sold per case year-over-year by 14%, more than offsetting 4% decrease in surgery volume;
- Continued sales network transformation, resulting in 15% year-over-year revenue growth from strategic distribution;
- Increased revenue from top 20 surgeons by 25% year-over-year; and
- Commenced significant upgrades of ATEC cervical portfolio sophistication with FDA 510(k) clearance of the InsigniaTM Anterior Cervical Plate System and InVictusTM CT Spinal Fixation System, which expands the elegance of InVictus across cervical, thoracic and lumbar procedures.
“I am proud of the way our team continues to methodically execute the plan,” said Pat Miles, Chairman and Chief Executive Officer. “Three years ago, we committed to creating clinical distinction, compelling surgeon adoption and revitalizing our sales channel. We described a time when unmatched procedural innovation would attract an increasingly influential surgeon base and a more professionalized salesforce, which would lead to increased case complexity, more products per procedure, and improved revenue per surgery. We’re beginning to see this vision reflected in our financial performance. While other companies commit to advertising campaigns, our commitment is to improving spine care. We are just getting started. We expect to see continued strong interest and enthusiasm for the 8 to 10 new solutions we will deliver in the second half of 2020. We could not be more viscerally and personally engaged in our mission and our ability to continue to drive industry-leading growth. We know our best is yet to come.”
Comparison of Selected GAAP and Non-GAAP Financial Results
for the Second Quarter 2020 to Second Quarter 2019
Revenue from U.S. products for the second quarter 2020 was $28.8 million, up 11% compared to $26.1 million in the second quarter 2019. Revenue growth generated by new products and the strategic distribution channel continues to outpace the ongoing revenue impacts of transitioning or discontinuing non-strategic distributor relationships.
Gross profit and gross margin from U.S. products for the second quarter 2020 were $20.8 million and 72.3%, respectively, compared to $18.8 million and 72.2%, respectively, for the second quarter 2019. On a non-GAAP basis, excluding non-cash excess and obsolete charges, U.S. gross margin was 78.2% in the second quarter of 2020, compared to 80.6% in the second quarter 2019. Non-GAAP U.S. gross margin was impacted by product mix and amortization of SafeOp-related intangibles, which commenced in late 2019.
Total operating expenses for the second quarter 2020 were $32.0 million compared to $29.3 million in the second quarter 2019. On a non-GAAP basis, excluding stock-based compensation, fair value adjustments, litigation-related expenses and transaction-related expenses, total operating expenses increased to $26.4 million from $25.8 million in 2019, reflecting increased selling costs from U.S. revenue growth, as well as increased investments in organic product development to support new product launches.
Non-GAAP adjusted operating loss, which excludes stock-based compensation, fair value adjustments, litigation-related expenses, transaction-related expenses and excess and obsolescence charges, was $3.7 million for the second quarter 2020, compared to a loss of $4.7 million for the second quarter 2019.
Non-GAAP adjusted EBITDA, which excludes stock-based compensation, fair value adjustments, litigation-related expenses, transaction-related expenses and excess and obsolescence charges in the second quarter 2020 was a loss of $1.1 million, compared to a loss of $3.0 million in the second quarter 2019.
For more detailed information on non-GAAP operating expenses, non-GAAP adjusted operating loss and non-GAAP adjusted EBITDA, please refer to the table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP Financial Measures,” that follows.
Cash and cash equivalents at June 30, 2020 were $31.2 million, with an additional $25 million available under the credit facility with Squadron Capital (the “Squadron facility”).
Current and long-term debt at face value as of June 30, 2020 includes $75 million in term debt under the Squadron facility. During the second quarter of 2020, the Company retired its revolving credit facility with MidCap Funding.
2020 Financial Outlook
As a result of hospitals globally postponing elective procedures to preserve capacity for COVID-19 patients, ATEC suspended its previously announced 2020 revenue guidance on April 8, 2020. While recovery of surgical volumes has been more robust than initially anticipated, the Company continues to have limited visibility into any continuing or future impact of the global pandemic.
Investor Conference Call
ATEC will present the results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At that time, please click here to access the live webcast. An audiocast of the presentation will be also be available domestically at (877) 556-5251 and internationally at (720) 545-0036. The conference ID number is 5682075.
A replay of the webcast will remain available on ATEC’s corporate website at www.atecspine.com until the Company releases second quarter financial results. In addition, a replay of the audiocast will be available until August 14, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 5682075.
